CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Sphenopalatine ganglion (SPG) nerve block for headache disorders

This policy governs coverage and medical necessity determinations for sphenopalatine ganglion (SPG) nerve block procedures applied intranasally for migraine, cluster, tension-type, postdural puncture, and other headache indications for Blue Cross Blue Shield - Rhode Island members.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicySphenopalatine ganglion (SPG) nerve block for headache disorders

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionFile claims with unlisted procedure code 64999 and verify member benefits and eligibility before providing non-covered services.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3FDA-cleared devices

12RCT treatments evaluated

9RCTs in PDPH review

64505, 64999Billing codes noted

21References listed

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Most recent guideline

Coverage Determination

Overall coverage determination

Covered when ALL of the following are met:

Coverage determination: Sphenopalatine ganglion (SPG) blocks are considered not covered or not medically necessary for all headache indications (including migraine, cluster, tension-type, postdural puncture headache, and other headache disorders) under Medicare Advantage and Commercial Products due to insufficient evidence to determine effects on health outcomes.

Randomized trials and systematic reviews show some short-term pain relief in selected studies (eg, single or short-term benefits up to 24 hours or within 4 hours for PDPH) but no consistent evidence of durable, long-term improvement in clinically meaningful outcomes; additional robust RCTs are needed.

Sphenopalatine ganglion (SPG) nerve blocks, when performed for any headache indication (including but not limited to migraine and non‑migraine headache disorders), are not covered / not medically necessary for Blue Cross Blue Shield — Rhode Island members. The documented rationale is that the current evidence is insufficient to determine the effects of SPG blocks on net health outcomes.

This determination applies broadly across evaluated headache indications and reflects the policy conclusion that published studies do not demonstrate consistent, durable benefit sufficient to support coverage.

Coverage and payment for services are governed by the member's subscriber agreement and any applicable employer agreement. Benefits and eligibility should be verified for each member; the subscriber agreement or evidence of coverage supersedes this medical policy.

If services are determined to be not medically necessary or otherwise non‑covered under the member's benefit documents, providers may not bill the member unless the member has been informed in advance and has provided written agreement to accept financial responsibility.

For Commercial Products specifically, SPG blocks are considered not medically necessary for all headache indications because available evidence is inadequate to demonstrate improvements in health outcomes.

Providers should therefore anticipate denials of coverage for these services under commercial product benefits unless the member's contract explicitly provides otherwise.

For Medicare Advantage Plans, SPG blocks are not covered for all headache indications, including migraine and non‑migraine headaches. The policy cites insufficient evidence to support coverage under Medicare Advantage.

Billing and Coding Guidance

Unlisted procedure code recommended for claimsCPT

64999

Unlisted procedure, nervous system

Code explicitly not covered / not medically necessaryCPTNot Covered

64505

Injection, anesthetic agent; sphenopalatine ganglion

Provider Responsibilities and Operational Notes

Prior Authorization

Prior Authorization and Benefits

Prior authorization is not applicable for this service; however, benefits may vary by contract. Verify member-specific benefits and prior authorization requirements with the member's plan before scheduling services.

Verify member benefits and eligibility with the provider call center prior to service
Obtain prior authorization if required by the member's specific plan or employer agreement

Prior Authorization

Prior Authorization Recommended

Although prior authorization is generally not applicable, obtain prior authorization when the member's contract or employer agreement requires it.

Contact the member's plan to confirm whether prior authorization is required for the submitted service

Note

Background and Context

Headache disorders are common neurologic conditions and encompass a range of diagnoses including tension‑type headache, cluster headache, and migraine. Chronic migraine is defined as headaches occurring on ≥15 days per month for more than 3 months, with migraine features present on at least 8 days per month.

Sphenopalatine ganglion (SPG) blocks are delivered by topical application of local anesthetic to the mucosa overlying the ganglion (for example via intranasal applicators or catheters) and have been studied for acute and chronic headache presentations. Available randomized trials and case series report short‑term symptom relief in some settings, but evidence is insufficient to demonstrate consistent long‑term benefit or improvement in net health outcomes.

Definitions

Chronic migraine definition

DefinitionAttacks on at least 15 days per month for more than 3 months, with features of migraine on at least 8 days per month.

Frequency threshold≥15 headache days per month for >3 months

Migraine-feature daysMigraine features present on ≥8 days per month

Classification source contextUsed to categorize migraine by frequency (chronic vs episodic) per headache disorder definitions.

Sphenopalatine ganglion (SPG) block — intranasal topical anesthetic

Procedure descriptionTopical application of local anesthetic to the mucosa overlying the sphenopalatine ganglion via an intranasal catheter or applicator.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicySphenopalatine ganglion (SPG) nerve block for headache disorders

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionFile claims with unlisted procedure code 64999 and verify member benefits and eligibility before providing non-covered services.

SourceLink

On This Page

Member Eligibility and Consent

Verify member eligibility, document informed consent when necessary, and confirm covered benefits before providing services.

Confirm eligibility and benefits via the provider call center or electronic eligibility tools
Obtain and document informed consent if services are non-covered or potentially not medically necessary

Denial Risk

Coverage Exclusion — Denial Risk

Sphenopalatine ganglion blocks for headache indications are excluded and will be denied when billed for migraine or non-migraine headache treatment.

Not covered / Not medically necessary for migraine and non-migraine headache indications

Billing Rule

Billing and Payment Risk

Claims submission guidance and billing risk: follow member contract and employer agreement; payment is not guaranteed. If services are determined not medically necessary or are non-covered, you may not bill the member unless the member was informed and agreed in writing to pay.

Payment is subject to member contract and employer agreement — not guaranteed
Do not bill the member for non-covered or not medically necessary services unless the member provided written agreement in advance

Documentation Required

Billing and Coding Documentation

Billing and coding: there is no specific CPT code for this procedure. Use the unlisted procedure code 64999 for claims. CPT code 64505 is not covered for Medicare Advantage Plans and is considered not medically necessary for Commercial Products.

File claims with CPT 64999 (Unlisted procedure, nervous system)
Do not use CPT 64505 — not covered / not medically necessary for these plans

Delivery methodInsert intranasal catheter attached to a syringe containing local anesthetic (eg, lidocaine or bupivacaine) and apply to posterior nasal cavity to reach the SPG.

Alternate historical techniqueOriginally performed with a cotton-tipped applicator dabbed with local anesthetic; considered less accurate than catheter-based methods.

Devices/examplesCommercially available catheters include Tx360, Allevio (SphenoCath), which differ in design but all deliver intranasal local anesthetic.

Postdural puncture headache (PDPH)

Clinical descriptionBilateral frontal or occipital headache that worsens with sitting or standing and is relieved in the supine position.

EtiologyDue to low cerebrospinal fluid volume/pressure from a dural puncture or CSF leak following lumbar puncture or unintended dural puncture during epidural anesthesia.

Associated symptomsMay include nausea, neck stiffness, low back pain, tinnitus, and visual disturbances.

Incidence noteReported incidence after lumbar puncture ranges from 10% to 40%; may be as low as 2% with small-gauge, non‑cutting needles.

sphenopalatine ganglion (SPG) block/stimulation — scope of procedures

Scope of proceduresProcedures targeting the sphenopalatine ganglion via trans-nasal (intranasal catheter/applicator), endoscopic approaches, percutaneous approaches, or implanted/stimulation devices.

Trans-nasal/intranasalTopical anesthetic delivered intranasally using catheters or applicators (eg, Tx360, Allevio, SphenoCath) to reach the SPG.

EndoscopicEndoscopic sphenopalatine ganglion block techniques described in literature for cluster headache and other indications.

Percutaneous and stimulation approachesPercutaneous interventional strategies and implanted neurostimulation of the SPG have been evaluated in systematic reviews and trials; some neurostimulation approaches are not FDA‑cleared in the U.S.